🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the effort against superbug strains of the pathogen, according to health experts.

A Global Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting more than 82 million new cases annually. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Clearance

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists hope that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in concurrent days. This medication, which is also used to treat UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Data and Global Access

Based on findings published in a major medical journal, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which uses two antibiotics. The trial involved over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of regions with limited resources.

Clinicians on the front lines have expressed optimism. Having a one-pill regimen of this kind is seen as a "revolutionary step" for managing the epidemic. This is viewed as crucial to reduce the burden of the disease for people and to halt the transmission of extremely resistant gonorrhoea worldwide.